» Articles » PMID: 33757859

Auto-antibodies to Post-translationally Modified Proteins in Osteoarthritis

Overview
Date 2021 Mar 24
PMID 33757859
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Autoantibodies (AutoAbs) have been observed in osteoarthritis (OA) with broad antigenicity, although their prevalence and role remain unclear. Post-translational modification (PTMs) of proteins (oxidation, carbamylation, citrullination) is associated with synovitis and can lead to AutoAb development. Given the prevalence of synovitis, we explored whether AutoAbs to PTM-antigens are common in OA compared with rheumatoid arthritis (RA).

Methods: Serum (n = 895) was obtained from healthy controls, OA and RA patients; and arthritic synovial fluid (SF, n = 290). ELISAs were used to quantify anti-citrullinated peptide (ACPA), anti-carbamylated protein (anti-CarP), anti-oxidized collagen (anti-ROS-CI/CII) antibodies.

Results: In sera, positivity for PTM-antigens AutoAbs was observed at a lower frequency in OA with 64.1% (95%CI: 57.2-70.1%) more ACPA+ and 29.8% (21.0-37.3%) more anti-CarP + patients in RA (both P < 0.0001). Levels of ACPA, anti-CarP were also lower in OA (P < 0.0001). Anti-ROS-CII positivity was lower in OA compared to RA (16.6%, 4.8-28.6%) less frequent, P = 0.033) but not anti-native-CII. There was no impact of age/gender on AutoAbs associations with diseases either looking at positivity or levels. In SF, OA patients were often ACPA+ (45.9%) although less frequently than in RA (P = 0.004). Anti-CarP were rarely observed (<5% all samples). All collagen AutoAbs were more frequent in RA compared to OA (all P < 0.010) but only levels of anti-CII and anti-ROS-CII were significantly higher in they RA (P < 0.050).

Conclusion: Although the frequency of AutoAbs for PTM proteins were lower in OA sera compared to RA, a higher proportion of OA SF were positive. The relative retention of AutoAbs in the OA joint requires further investigation.

Citing Articles

circ_0075048 silencing regulates LCP1 to improve IL-1β-induced chondrocyte injury by binding with miR-663b.

Zhang P, Pei R, Shen Q J Orthop Surg Res. 2025; 20(1):24.

PMID: 39780251 PMC: 11715223. DOI: 10.1186/s13018-025-05449-0.


Unravelling the ties that bind: The intersection of obesity, osteoarthritis, and inflammatory pathways with emphasis on glucagon-like peptide-1 agonists.

Jamal N, Hollabaugh W, Scott L, Takkouche S Clin Obes. 2024; 15(1):e12700.

PMID: 39152660 PMC: 11706737. DOI: 10.1111/cob.12700.


Lymphatic vessels: roles and potential therapeutic intervention in rheumatoid arthritis and osteoarthritis.

Zhou S, Zhao G, Chen R, Li Y, Huang J, Kuang L Theranostics. 2024; 14(1):265-282.

PMID: 38164153 PMC: 10750203. DOI: 10.7150/thno.90940.


Clinical diagnoses associated with a positive antinuclear antibody test in patients with and without autoimmune disease.

Zanussi J, Zhao J, Wei W, Karakoc G, Chung C, Feng Q BMC Rheumatol. 2023; 7(1):24.

PMID: 37550754 PMC: 10405518. DOI: 10.1186/s41927-023-00349-4.


B cells in osteoarthritis: simply a sign or a target for therapy?.

Burt K, Scanzello C Osteoarthritis Cartilage. 2023; 31(9):1148-1151.

PMID: 37328048 PMC: 10680778. DOI: 10.1016/j.joca.2023.06.002.